Literature DB >> 9881484

Regression of hepatic fibrosis in hepatitis C with long-term interferon treatment.

J F Dufour1, R DeLellis, M M Kaplan.   

Abstract

Cirrhosis occurs in 20-50% of patients with hepatitis C and is thought to be irreversible. We describe two patients with cirrhosis secondary to hepatitis C in whom the extensive fibrosis and cirrhosis appeared to regress in response to treatment with interferon-alpha (IFN-alpha). Both patients were in the early stages of cirrhosis, class A in the Child-Pugh classification, total score 5 for each patient. Both responded fully to IFN-alpha and had normalization of all liver function tests and disappearance of hepatitis C viral RNA. Liver biopsies, performed before and after treatment, were coded unpaired by patient, combined with 21 liver biopsies from eight other patients with chronic hepatitis, and read independently by two pathologists using the Knodell scoring system. Knodell scores decreased from 14 to 3.5 and from 13.5 to 4 in these two patients. Cirrhosis and extensive fibrosis, present at baseline, were not present on follow-up liver biopsies, which were of sufficient size to reduce the likelihood of sampling error. We conclude that hepatic fibrosis and clinically early cirrhosis may be reversible in some patients with hepatitis C who respond to treatment with IFN-alpha.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9881484     DOI: 10.1023/a:1026601904609

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  15 in total

1.  Sustained biochemical and histologic remission of primary biliary cirrhosis in response to medical treatment.

Authors:  M M Kaplan; R A DeLellis; H J Wolfe
Journal:  Ann Intern Med       Date:  1997-05-01       Impact factor: 25.391

2.  A histopathological study of the effects of 6-month versus 12-month interferon alpha-2b therapy in chronic hepatitis C.

Authors:  M Ziol; J T Nhieu; F Roudot-Thoraval; J M Métreau; Y Deugnier; D Dhumeaux; E S Zafrani
Journal:  J Hepatol       Date:  1996-12       Impact factor: 25.083

3.  Penicillamine-induced normalization of clinical signs, and liver morphology and histochemistry in a case of Wilson's disease.

Authors:  S Falkmer; G Samuelson; S Sjölin
Journal:  Pediatrics       Date:  1970-02       Impact factor: 7.124

4.  Reversal of "cirrhosis" in idiopathic haemochromatosis following long-term intensive venesection therapy.

Authors:  L W Powell; J F Kerr
Journal:  Australas Ann Med       Date:  1970-02

5.  Randomised trial of lymphoblastoid alpha-interferon in chronic hepatitis C. Effects on inflammation, fibrogenesis and viremia.

Authors:  J Camps; A Castilla; J Ruiz; M P Civeira; J Prieto
Journal:  J Hepatol       Date:  1993-03       Impact factor: 25.083

6.  Interferon alfa and gamma inhibit proliferation and collagen synthesis of human Ito cells in culture.

Authors:  A Mallat; A M Preaux; S Blazejewski; J Rosenbaum; D Dhumeaux; P Mavier
Journal:  Hepatology       Date:  1995-04       Impact factor: 17.425

7.  A comparison of three interferon alfa-2b regimens for the long-term treatment of chronic non-A, non-B hepatitis. Multicenter Study Group.

Authors:  T Poynard; P Bedossa; M Chevallier; P Mathurin; C Lemonnier; C Trepo; P Couzigou; J L Payen; M Sajus; J M Costa
Journal:  N Engl J Med       Date:  1995-06-01       Impact factor: 91.245

8.  Clinical outcomes after transfusion-associated hepatitis C.

Authors:  M J Tong; N S el-Farra; A R Reikes; R L Co
Journal:  N Engl J Med       Date:  1995-06-01       Impact factor: 91.245

9.  Improvement of liver fibrosis in chronic hepatitis C patients treated with natural interferon alpha.

Authors:  N Hiramatsu; N Hayashi; A Kasahara; H Hagiwara; T Takehara; Y Haruna; M Naito; H Fusamoto; T Kamada
Journal:  J Hepatol       Date:  1995-02       Impact factor: 25.083

10.  Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis.

Authors:  R G Knodell; K G Ishak; W C Black; T S Chen; R Craig; N Kaplowitz; T W Kiernan; J Wollman
Journal:  Hepatology       Date:  1981 Sep-Oct       Impact factor: 17.425

View more
  29 in total

Review 1.  Is liver fibrosis reversible?

Authors:  R C Benyon; J P Iredale
Journal:  Gut       Date:  2000-04       Impact factor: 23.059

2.  Utility of diffusion-weighted imaging in the evaluation of liver fibrosis.

Authors:  Ayse Ahsen Bakan; Ercan Inci; Selim Bakan; Suut Gokturk; Tan Cimilli
Journal:  Eur Radiol       Date:  2011-10-09       Impact factor: 5.315

3.  Histological outcome of chronic hepatitis B in children treated with interferon alpha.

Authors:  Sobaniec-Lotowska Maria Elzbieta; Lebensztejn Dariusz Marek
Journal:  World J Gastroenterol       Date:  2005-12-07       Impact factor: 5.742

Review 4.  An appraisal of the histopathological assessment of liver fibrosis.

Authors:  R A Standish; E Cholongitas; A Dhillon; A K Burroughs; A P Dhillon
Journal:  Gut       Date:  2006-04       Impact factor: 23.059

5.  Clinical and Pathological Risk Factors Associated with Liver Fibrosis and Steatosis in African-Americans with Chronic Hepatitis C.

Authors:  Ali Afsari; Edward Lee; Babak Shokrani; Tina Boortalary; Zaki A Sherif; Mehdi Nouraie; Adeyinka O Laiyemo; Kawtar Alkhalloufi; Hassan Brim; Hassan Ashktorab
Journal:  Dig Dis Sci       Date:  2017-06-13       Impact factor: 3.199

6.  Matrix-derived serum markers in monitoring liver fibrosis in children with chronic hepatitis B treated with interferon alpha.

Authors:  Dariusz-Marek Lebensztejn; Maria-Elzbieta Sobaniec-Lotowska; Maciej Kaczmarski; Michael Voelker; Detlef Schuppan
Journal:  World J Gastroenterol       Date:  2006-06-07       Impact factor: 5.742

7.  Sustained virologic response to peginterferon alpha-2a and ribavirin in 335 patients with chronic hepatitis C: a tertiary care center experience.

Authors:  Hamad Al Ashgar; Mohammed Q Khan; Ahmed Helmy; Khalid Al Swat; Abdullah Al Shehri; Abdalla Al Kalbani; Musthafa Peedikayel; Khalid Al Kahtani; Mohammed Al Quaiz; Mohammed Rezeig; Ingvar Kagevi; Mohammed Al Fadda
Journal:  Saudi J Gastroenterol       Date:  2008-04       Impact factor: 2.485

8.  Reversal of liver fibrosis.

Authors:  Mona H Ismail; Massimo Pinzani
Journal:  Saudi J Gastroenterol       Date:  2009-01       Impact factor: 2.485

9.  Regression of fibrosis in paediatric autoimmune hepatitis: morphometric assessment of fibrosis versus semiquantiatative methods.

Authors:  Ahmed F Abdalla; Khaled R Zalata; Abeer F Ismail; Gamal Shiha; Mohamed Attiya; Ahmed Abo-Alyazeed
Journal:  Fibrogenesis Tissue Repair       Date:  2009-04-02

10.  Predictors of sustained virological response to a 48-week course of pegylated interferon alfa-2a and ribavirin in patients infected with hepatitis C virus genotype 4.

Authors:  Hamad Al Ashgar; Ahmed Helmy; Mohamed Q Khan; Khalid Al Kahtani; Mohammed Al Quaiz; Mohammed Rezeig; Ingvar Kagevi; Abdullah Alshehri; Abdullah Al Kalbani; Khalid Al Swat; Salim Dahab; Naser Elkum; Mohammed Al Fadda
Journal:  Ann Saudi Med       Date:  2009 Jan-Feb       Impact factor: 1.526

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.